Heidi S. Camp

Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome

Barbara L. Cool, Bradley A. Zinker, William J. Chiou et al. · Cell Metabolism · 2006 · 918 citations · Full text

Medicine, Biochemistry, Pharmacology +14

Regulation of Peroxisome Proliferator-activated Receptor γ Activity by Mitogen-activated Protein Kinase

Heidi S. Camp, Sherrie Tafuri · Journal of Biological Chemistry · 1997 · 448 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +16

Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial

Gerd R Burmester, Joel M. Kremer, Filip Van den Bosch et al. · The Lancet · 2018 · 397 citations

Medicine, Internal Medicine, Pharmacology +13

Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study

Josef S Smolen, Aileen L. Pangan, Paul Emery et al. · The Lancet · 2019 · 378 citations

Medicine, Pharmacology, Pharmacotherapy +10

In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)

Julie Parmentier, J W Voss, Candace Graff et al. · BMC Rheumatology · 2018 · 374 citations · Full text

Medicine, Immunology, Pharmacology +16